A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naive Subjects With Moderately-to-Severely Active Crohn's Disease

Trial Profile

A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naive Subjects With Moderately-to-Severely Active Crohn's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs Ustekinumab (Primary) ; Adalimumab
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms SEAVUE
  • Sponsors Janssen
  • Most Recent Events

    • 30 Jul 2018 New source identified and integrated (European Clinical Trials Database: EudraCT2017-004209-41).
    • 18 Apr 2018 Planned End Date changed from 15 Oct 2020 to 1 Dec 2020.
    • 18 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top